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Abstract
Background: Glycated hemoglobin (HbA1c) results vary by analytical method. Use of same-visit
HbA1c testing methodology holds the promise of more efficient patient care, and improved
diabetes management. Our objective was to test the feasibility of introducing a same-visit HbA1c
methodology into busy family practice centers (FPC) and to calculate the correlation between the
same-visit HbA1c test and the laboratory method that the clinical site was currently using for
HbA1c testing.
Methods: Consecutive diabetic patients 18 years of age and older having blood samples drawn for
routine laboratory analysis of HbA1c were asked to provide a capillary blood sample for same-visit
testing with the BIO-RAD Micromat II. We compared the results of the same-visit test to three
different laboratory methods (one FPC used two different laboratories).
Results: 147 paired samples were available for analysis (73 from one FPC; 74 from the other). The
Pearson correlation of Micromat II and ion-exchange HPLC was 0.713 (p < 0.001). The Micromat
II mean HbA1c was 6.91%, which was lower than the 7.23% from the ion-exchange HPLC analysis
(p < 0.001). The correlation of Micromat II with boronate-affinity HPLC was 0.773 (p < 0.001);
Micromat II mean HbA1c 6.44%, boronate-affinity HPLC mean 7.71% (p < 0.001). Correlation
coefficient for Micromat II and immuno-turbidimetric analysis was 0.927 (p < 0.001); Micromat II
mean HbA1c was 7.15% and mean HbA1c from the immuno-turbidimetric analysis was 7.99% (p =
0.002). Medical staff found the same-visit measurement difficult to perform due to the amount of
dedicated time required for the test.
Conclusion: For each of the laboratory methods, the correlation coefficient was lower than the
0.96 reported by the manufacturer. This might be due to variability introduced by the multiple users
of the Micromat II machine. The mean HbA1c results were also consistently lower than those
obtained from laboratory analysis. Additionally, the amount of dedicated time required to perform
the assay may limit its usefulness in a busy clinical practice. Before introducing a same-visit HbA1c
methodology, clinicians should compare the rapid results to their current method of analysis.
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Background
The percent HbA1c of glycated hemoglobin provides an
estimate of blood glucose levels over a 3–4 month period.
The HbA1c level is used for patient education and coun-
seling, for feedback about diabetic control, to improve
patient motivation, and to monitor management; thus its
measurement should be optimally accurate and precise
[1]. However, to date, there is no international standard
for determining HbA1c [2-4], and various methodologies
are commercially available. Tran [1] determined the phys-
iological (changes over time between measurements) and
analytic variation of two widely used laboratory assays,
one a high performance liquid chromatography (HPLC)
method, and the other an immunoassay [1]. The coeffi-
cient of variation (CV) for the HPLC was 2.6%. The 5.1%
CV of the immunoassay method exceeded physiologically
established limits of 2–3%, and those of the National Gly-
cohemoglobin Standardization Program (3–4%).
Hosseini et al. [5] reported a relative ranking of assays to
result in a normal HbA1c level by using the same patient's
blood tested with five assays, each of which used a differ-
ent method. They found that glycated hemoglobin results
vary widely, with some assays consistently more likely to
result in a "normal glycated hemoglobin" level than other
assays, consequently resulting in differing implications
for an individual patient to achieve a HbA1c level within
the normal range. Ogawa [6] reported a case series where
HbA1c was underestimated in the measurement by HPLC
which excluded glycated abnormal hemoglobin [6]. These
findings illustrate the potential usefulness for clinical
practitioners to evaluate the performance of their method
for determining HbA1c, especially if using different meth-
odologies for the same patient.
Recent developments in medical technology allow clini-
cians to determine HbA1c test results during a patient's
office visit. Several manufacturers offer an assay that can
be performed by trained medical personnel and yield
HbA1c results in five to ten minutes. We found only a few
reports of the performance of such rapid tests used at the
point of care [7,8], and one study that was conducted by
the test manufacturer [9].
The objective of this pilot study was to test the feasibility
of introducing a same-visit HbA1c methodology into busy
family practice centers (FPCs) and to compare the results
obtained from a point-of-care test with a laboratory-based
technique. Specifically, our purpose was to determine: 1)
if a specific rapid HbA1c methodology was accepted by
medical support staff in two busy FPCs; and 2) how rapid
HbA1c results compared with the standard laboratory
methodology.
Methods
Study design
Patients were recruited for this cross-sectional study from
two FPCs that are members of MetroNet, a metropolitan
Detroit practice-based research network. At both sites,
HbA1c analysis is routinely performed at an outside labo-
ratory on venipuncture samples. Physicians, medical
assistants, and research assistants identified consecutive
diabetic patients 18 years of age and older whose physi-
cians ordered HbA1c analysis. The study was explained to
these eligible patients and informed consent obtained
from those who wished to participate.
After patients were enrolled, a finger-prick blood sample
was collected for in-office HbA1c testing with the BIO-
RAD Micromat II. Since the BIO-RAD Micromat II is com-
patible with capillary, venous, and EDTA anti-coagulated
blood samples, aliquots of these types were also accepta-
ble for analysis. Research and medical staff were
instructed to use finger-prick capillary samples whenever
possible, but venous samples from the blood draw appa-
ratus, or a drop of blood from the EDTA tube was substi-
tuted when necessary. At one FPC only finger-prick
samples were used, while at the other FPC, thirteen Micro-
Mat II samples were venous and five were EDTA anti-coag-
ulated; the remaining 56 tests were performed using
capillary blood samples.
The data collected included patient name, study site, the
person performing same-visit HbA1c analysis, the date,
and the rapid HbA1c result. Physicians were blinded to
rapid HbA1c results, and relied on the laboratory analysis
to make treatment decisions during the study period. One
FPC used one of two different laboratories based on the
patient's health insurance carrier. At one laboratory, the
Primus Model 386 was used for HbA1c testing, which is a
boronate – affinity HPLC method. The other laboratory
used the Roche Integra 800, which uses an immuno-turbi-
dimetric methodology. The laboratory of the second FPC
used the Tosoh A1c 2.2 Plus, an ion-exchange HPLC, for
analysis.
All three methodologies are aligned to Diabetes Control
and Complications Trial (DCCT) and National Glycohe-
moglobin Standardization Program (NGSP) standards.
All have linear response from HbA1c level of 3–4% to
20% or higher. The intra- and inter-assay coefficients of
variation are displayed in Table 1. These values were either
obtained directly from the laboratory performing the
assay (Primus 386) or from the manufacturer. All are
within NGSP acceptable limits.
The BIO-RAD Micromat II, which provides results in
approximately 5 minutes, incorporates an affinity chro-
matography method that measures the percent glycatedBMC Family Practice 2005, 6:28 http://www.biomedcentral.com/1471-2296/6/28
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hemoglobin in the sample. According to the manufac-
turer, the analyzer then uses a factory-set algorithm to
deliver an HbA1c result which is calibrated to the recom-
mendations of the DCCT and is traceable to the NGSP.
The intra-assay coefficient of variation is reported to range
from 2.93 – 4.65%; higher at lower values of HbA1c. The
inter-assay coefficient of variation is estimated to be
higher; however values are not given in the package insert.
The sensitivity of the assay ranges from 4 – 15% HbA1c.
BIO-RAD representatives provided an in-service to help
familiarize staff in the use and operation of the Micromat
II analyzer.
Each HbA1c analysis with the Micromat II requires a sin-
gle test cartridge, which consists of several tubes with rea-
gents that are mixed and decanted into a collection
reservoir for measurement. After a test cartridge has been
placed into the Micromat II, a 20 microliter blood sample
is added to the first tube. This initiates a series of aliquot
additions and incubation steps. In total there are four
decanting steps followed by four incubations. These incu-
bations require a total time of 230 seconds and range
from 40 seconds to 80 seconds in length. Quality control
procedures were carried out as outlined in the Micromat II
instruction manual. Controls and standards were run per
Table 1: Coefficients of variation (CV) for three laboratory analyzers
Instrument Method Intra-assay CV Inter-assay CV
Primus 386 Boronate affinity HPLC 0.9% 2.9%
Roche Integra 800 Immuno-turbidimetric 2.3% 2.4%
Tosoh A1c2.2 Plus Ion-exchange HPLC 1.3% < 4.0%
Scatterplot and regression line of HbA1c values produced from boronate affinity HPLC and Micromat II Figure 1
Scatterplot and regression line of HbA1c values produced from boronate affinity HPLC and Micromat II.
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the manufacturer's recommendation; results were always
acceptable.
Analytic strategy
Data were analyzed separately by type of laboratory meth-
odology. To evaluate the performance of the BIO-RAD
Micromat II, Pearson correlations were calculated using
the laboratory results as the standard. Scatter plots and
regression lines were also examined. The mean absolute
difference between the sample groups was determined to
test the hypothesis that group means are equal (α = 0.05),
using a two-sided paired t-test.
Results
One hundred fifty-six patients were enrolled into the
study (75 from one FPC, and 81 from the other FPC).
Nine different medical staff performed the rapid HbA1c
testing. Data from nine patients were omitted: eight had
missing laboratory results, and one result was out of the
precision range of the machine (HbA1c = 18.1%). There-
fore, 147 paired samples were available for analysis, 73
from one site and 74 from the other.
Considering first the data from the site that used two dif-
ferent laboratories: the boronate-affinity HPLC (n = 63)
and the immuno-turbidimetric (n = 11), we found a sig-
nificant correlation with the Micromat II results for both
(Pearson r = 0.773, p < 0.001 and r = 0.927, p < 0.001,
respectively) (Figures 1 and 2). The range of values was
from 2.3% to 12.70%. The laboratory method yielded a
mean HbA1c value that was significantly higher than that
from the Micromat II for both methodologies (7.71 ± 1.99
vs. 6.44 ± 1.99, p < 0.001 and 7.99 ± 1.76 vs. 7.15 ± 1.72,
p = 0.002, respectively (Table 1). Similarly, the Micromat
II correlated well with the ion-exchange HPLC (n = 73,
Pearson r = 0.713, p < 0.001) (Figure 3). Again, the mean
HbA1c result from the laboratory was significantly greater
than the mean from the Micromat II (7.23 ± 1.51 vs. 6.91
± 1.34, p = 0.014). The range of results from these two
methods was 3.6% to 15.80%.
Regarding feasibility and acceptability of introducing the
same-visit Micromat II test into the busy clinical practice
setting, we found that medical assistants were able to col-
lect and analyze samples and produce same-visit results.
However, the five minute time dedication for each indi-
Scatterplot and regression line of HbA1c values produced from immuno-turbidimetric and Micromat II methods Figure 2
Scatterplot and regression line of HbA1c values produced from immuno-turbidimetric and Micromat II methods.
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vidual analysis was not well tolerated by staff because of
numerous competing demands that made it difficult to
perform all the test steps in the time intervals prescribed.
Discussion
Physicians in ambulatory settings routinely send blood
samples to laboratories for HbA1c testing, and then wait
several days for the HbA1c test results. Thus, patient coun-
seling and treatment adjustments based on HbA1c levels
are delayed, and at times follow-up can be lost
completely.
Recent advancements in technology now make it possible
for physicians to incorporate point-of-care HbA1c results
to evaluate and adjust treatment of their diabetic patients.
Studies of the effect of same-visit HbA1c measurement
found significantly improved glycemic control through
12-month follow-up [10,11]. This technology is gaining
acceptance, and is now offered by a number of
manufacturers. The same-visit HbA1c test provides the
opportunity to improve diabetes care by discussing the
value and adjusting management as needed during the
same-visit, rather than waiting until the patient can be tel-
ephoned and/or scheduled for a future visit. HbA1c test-
ing has been studied for its effect on improved glycemic
control in trials primarily conducted in specialty clinics.
Yet, little is published regarding the validity of the same-
visit test result, and the feasibility of using a same-visit
methodology in a busy primary care setting.
The manufacturer reports a correlation coefficient of 0.96
between the BIO-RAD Micromat II and HPLC methodol-
ogy. However, the correlation coefficients we obtained in
this clinical situation (r = 0.713; and r = 0.773 for the two
different HPLC methods) were less than reported by the
company. The highest correlation was with the immuno-
turbidimetric methodology (r = 0.927). The mean HbA1c
level obtained from Micromat II was significantly lower
than that yielded from the three types of laboratory anal-
ysis, and this difference spanned the treatment threshold
level currently recommended by the American Diabetes
Association (ADA) [12]. Thus, for some patients, the
Micromat II rapid test yielded a test result that was below
the ADA treatment threshold of 7%, while the laboratory
analysis produced a test result above 7%, suggesting the
need for more intensive therapy.
Scatterplot and regression line of HbA1c values produced from ion-exchange HPLC and Micromat II methods Figure 3
Scatterplot and regression line of HbA1c values produced from ion-exchange HPLC and Micromat II methods.
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Limitations
There are likely limitations to the generalizability of the
study findings. First, the number of medical staff (n = 9)
that collected samples and performed the HbA1c testing
may have increased the variability of the same-visit test
results. Similarly, the correlation between the laboratory
and the same-visit methodologies may be improved when
conducted under ideal conditions where sources of varia-
tion in the operation of the Micromat II are minimized.
Secondly, introducing a research study into a busy clinical
practice setting is often met with varying degrees of resist-
ance. Thus, evaluating the acceptance of what may have
been viewed by staff as a research technique may have
limitations when generalizing the acceptance of a clinical
procedure. However, our purpose was to conduct a corre-
lation study in the real world setting of the busy FPC. We
trained all clinical staff in the calibration and specimen
analysis of the point-of-care instrument. From discussions
with the clinical staff and physicians, we learned that there
was variability among staff members to faithfully adhere
to the Micromat II timed steps as outlined in the test kit
instructions.
Conclusion
Same-visit HbA1c testing offers potential benefits for dia-
betes care, as patient results are available in the same-visit.
However, clinicians should be aware that the rapid HbA1c
technology may produce results that are lower than the
method that they have been utilizing, and that the same-
visit test may suggest a different treatment strategy than a
result from their usual laboratory testing source. To over-
come this barrier, we suggest that clinicians determine
how the results of a same-visit HbA1c test compare with
the outside laboratory reports on which they routinely
base their treatment plans before incorporating the same-
visit HbA1c test into their practice.
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